Camber launches generic Nimbex injection
The launch expands Camber’s hospital and acute care products and provides healthcare providers access to a widely used neuromuscular blocking agent for anesthesia and critical care.
Camber Pharmaceuticals
Camber strengthens portfolio with the launch of five new generic medications in May
By expanding treatment options and increasing availability of essential therapies, Camber continues to support healthcare providers, pharmacies, and patients across the country.
Q&A with Kon Ostaficiuk, President, Camber Pharmaceuticals
Camber Pharmaceuticals aims to expand in the U.S. generics market. President Kon Ostaficiuk highlights a strategy focused on scale, speed, and competitiveness.
Camber offers Q1 recap
New launches emphasize Camber’s continued investment in expanding patient access to high-quality, affordable treatments.
Camber expands portfolio
New launches of Plerixafor Injection, Baclofen Tablets, Fluvoxamine Maleate ER Capsules, and Olmesartan Hydrochlorothiazide Tablets.
Camber Pharmaceuticals launches Pomalidomide Capsules
Pomalidomide capsules are available in 1 mg, 2 mg, 3 mg, and 4 mg strengths in bottles of 21 capsules.
Camber launches Sodium Oxybate Oral Solution
Sodium Oxybate Oral Solution 0.5 g/mL is available in 180 mL bottles and is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy.
Camber launches Voriconazole for oral suspension
Voriconazole for Oral Suspension treats yeast and fungal infections in adults and children 2 years and older, especially in cases of intolerance or resistance to other treatments.
Camber launches Spironolactone Tablets
Spironolactone Tablets are indicated for treatment of Heart Failure, Hypertension, Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome, and Primary Hyperaldosteronism.
Camber Pharmaceuticals reviews 2025 achievements and plans 2026 growth
Camber’s year featured broad generic launches, specialty and oncology introductions, emphasizing access, affordability, and supply reliability in the U.S.
Camber awarded 2025 “Large Supplier of the Year” by the Premier Group
“This award is a direct result of strong collaboration and shared accountability,” said Stu Messinger, Director of National Accounts.
Camber launches Nilotinib capsules
Camber Pharmaceuticals continues to strengthen its range of treatment options.
Camber launches Eletriptan Hydrobromide Tablets
The tablets are indicated for the acute treatment of migraine, with or without aura, in adults.
Camber introduces Abacavir and Lamivudine Tablets, USP
Abacavir/Lamivudine Tablets, USP are indicated for treating HIV-1 infection.
Hetero and the Gates Foundation partner to expand HIV prevention access
Hetero, parent of Camber Pharmaceuticals, is a global leader in antiretroviral (ARV) therapy, supplying around 40% of worldwide HIV and AIDS medicines.
Camber adds 800 mg Darunavir tablets to product family
Darunavir Tablets are the generic equivalent of Prezista.